Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor α-mediated sensitization of human breast cancer cells to chemotherapy

Cancer Research

Volumn 66, Issue 20, 2006, Pages 10092-10099

  Xu, Jing ^a   Zhou, Jun Ying ^a   Wu, Gen Sheng ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE PHASE; CELL DEATH; CHEMOSENSITIVITY; CHROMATIN IMMUNOPRECIPITATION; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG MIXTURE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASPASES; CELL DEATH; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; NF-KAPPA B; PROMOTER REGIONS (GENETICS); TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750535200     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1633     Document Type: Article

References (38)

1. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-63.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
3. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
4. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
5. Wu GS, Burns TF, McDonald ER, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3.
6. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272:25417-20.
7. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8.
8. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-97.
9. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997;7:693-6.
10. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-70.
11. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
12. Mongkolsapaya J, Cowper AE, Xu XN, et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 1998;160:3-6.
13. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEES Lett 1998;424:41-5.
14. Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997;7:1003-6.
15. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20.
16. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
17. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999;59:2770-5.
18. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
19. Bodmer JL, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241-3.
20. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-20.
21. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12:599-609.
22. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-7.
23. Schmelz K, Wieder T, Tamm I, et al. Tumor necrosis factor α sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-κB. Oncogene 2004;23:6743-59.
24. Sun SY, Yue P, Zhou J-Y, et al. Overexpression of bcl2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001;280:788-97.
25. Yin W, Rossin A, Clifford JL, Gronemeyer H. Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM. Oncogene 2006;25:3735-44.
26. Ding Z, Zhou JY, Wei WZ, Baker W, Wu GS. Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines. Oncogene 2002;21:4530-8.
27. Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 2002;21:1-8.
28. Li M, Zhou JY, Ge Y, Matherly LH, Wu GS. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 2003;278:41059-68.
29. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
30. Baetu TM, Kwon H, Sharma S, Grandvaux N, Hiscott J. Disruption of NF-κB signaling reveals a novel role for NF-κB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 2001;167:3164-73.
31. Gong B, Almasan A. Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 2000;278:747-52.
32. Wang Q, Ji Y, Wang X Evers BM. Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 2000;276:466-71.
33. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004;23:3051-60.
34. Kirshner JR, Karpova AY, Kops M, Howley PM. Identification of TRAIL as an Interferon regulatory factor 3 transcriptional target. J Virol 2005;79:9320-4.
35. Rivera-Walsh I, Waterfield M, Xiao G, Fong A, Sun SC. NF-κB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I Tax-induced T-cell death. J Biol Chem 2001;276:40385-8.
36. Ping D, Boekhoudt G, Zhang F, et al. Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor. J Biol Chem 2000;275:1708-14.
37. Ainbinder E, Revach M, Wolstein O, Moshonov S, Diamant N, Dikstein R. Mechanism of rapid transcriptional induction of tumor necrosis factor a-responsive genes by NF-κB. Mol Cell Biol 2002;22:6354-62.
38. Ten Hagen TL, Van Der Veen AH, Nooijen PT, Van Tiel ST, Seynhaeve AL, Eggermont AM. Low-dose tumor necrosis factor-α augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000;87:829-37.